Nodular Sclerosis Hodgkin Lymphoma, Spleen (C81.17)

Name of the Condition

• Common Name: Nodular Sclerosis Hodgkin Lymphoma, Spleen
• Medical Terms: Nodular Sclerosis Hodgkin's Disease, NSHL (Spleen Involvement)

Summary

Nodular sclerosis Hodgkin lymphoma (NSHL) is a subtype of Hodgkin lymphoma defined by Reed-Sternberg cells and a fibrous nodular pattern in affected lymph nodes. This specific code (C81.17) indicates involvement of the spleen. NSHL is the most common subtype of Hodgkin lymphoma and typically presents with painless lymph node enlargement, often in the mediastinum or neck. Spleen involvement may occur as part of systemic disease spread. NSHL tends to affect young adults and has a favorable prognosis with standard treatment.

Causes

The exact cause of NSHL is not fully understood, but it is believed to result from a combination of genetic and environmental factors. Viral infections, such as Epstein-Barr virus (EBV), may contribute to its development, though not all cases are associated with EBV. Genetic predisposition and immune system interactions are also thought to play a role.

Risk Factors

• Age: Most commonly diagnosed in young adults (15-35 years) and adolescents.
• Gender: Slightly more prevalent in females.
• Family History: Having a first-degree relative with lymphoma may increase risk.
• Epstein-Barr Virus: Prior infection may elevate susceptibility.

Symptoms

• Painless swelling of lymph nodes, often in the neck, armpits, or chest.
• Persistent fatigue or weakness.
• Unexplained fever or night sweats.
• Unintentional weight loss.
• Enlarged spleen (splenomegaly) may cause abdominal discomfort or fullness.
• Pruritus (itching) in some cases.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT scans, PET scans), and tissue biopsy. A biopsy of an affected lymph node or spleen tissue is essential to confirm the presence of Reed-Sternberg cells and the characteristic nodular sclerosis pattern. Staging procedures assess the extent of disease, including spleen involvement. Blood tests may evaluate blood cell counts and organ function.

Treatment Options

Treatment depends on the stage and may include chemotherapy, often with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or similar regimens. Radiation therapy may be used for localized disease or as an adjunct. Stem cell transplantation is considered for relapsed or refractory cases. Treatment plans are individualized based on patient factors and disease characteristics.

Prognosis and Follow-Up

NSHL has a favorable prognosis, with high cure rates, especially in early-stage disease. Prognosis depends on factors like stage, response to treatment, and patient age. Follow-up includes regular monitoring with physical exams, imaging, and blood tests to detect recurrence. Long-term survivors may require surveillance for late effects of treatment.

Complications

• Infection risk due to immunosuppression from treatment.
• Secondary cancers (e.g., leukemia) from chemotherapy or radiation.
• Infertility (potential side effect of certain treatments).
• Cardiovascular or pulmonary issues from radiation or chemotherapy.
• Spleen-related complications, such as rupture or hypersplenism.

Lifestyle & Prevention

• Maintain a balanced diet and regular exercise to support overall health during and after treatment.
• Avoid exposure to infections; practice good hygiene and consider vaccinations as recommended.
• Limit alcohol and avoid smoking to reduce additional health risks.
• Follow medical advice regarding activity levels and rest.

When to Seek Professional Help

Seek immediate medical attention for:

• Sudden, severe abdominal pain (possible spleen rupture).
• High fever, chills, or signs of infection.
• Unexplained weight loss, night sweats, or persistent fatigue.
• New or worsening lymph node swelling.
• Shortness of breath or chest discomfort.

Tips for Medical Coders

Use C81.17 for cases of nodular sclerosis Hodgkin lymphoma with confirmed spleen involvement. Document the site of involvement clearly in the medical record. Ensure differentiation from other lymphoma subtypes or non-Hodgkin lymphomas. Verify that spleen involvement is explicitly stated or confirmed through imaging/biopsy to support code assignment.